Fulcrum Therapeutics (FULC) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 18.3% versus a loss of 60.3%. Over five years, FULC leads with a -85.9% price change compared with -98.2% for XFOR. Fulcrum Therapeutics is the larger company by market cap ($280.0 million vs $278.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | XFOR |
|---|---|---|
| Share price | $3.67 | $2.81 |
| Market cap | $280.01M | $278.60M |
| 1-day change | -0.54% | +1.44% |
| YTD return | -67.55% | -29.75% |
| 1-year return | -60.28% | -18.31% |
| 5-year return | -85.88% | -98.21% |
| P/E ratio (TTM) | — | 140.50 |
| EPS (TTM) | $-1.21 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $4.83 |
| 52-week low | $2.83 | $2.70 |
| Distance from 52-week high | -76.68% | -41.82% |
| Analyst consensus | none | none |
| Avg. price target upside | 0.00% | +312.81% |
| Average volume | 1.53M | 849.98K |
| Shares outstanding | 76.30M | 99.15M |
| Employees | 9 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed FULC by 42.0 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
FULC vs XFOR FAQ
Which is bigger, Fulcrum Therapeutics or X4 Pharmaceuticals?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $280.01M compared with $278.60M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, FULC or XFOR?
XFOR returned -18.31% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Fulcrum Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.